CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and empathetically with patients navigating a chronic ...
For most people, a cancer diagnosis—especially one such as chronic lymphocytic leukemia (CLL), a slow-growing type of blood cancer—sets off a flood of emotions. According to a 2022 Emotional Impact ...
In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...
The Test Before Treat campaign highlights how a patient’s genetic profile can change over time and encourages the use of a blood test to identify mutations to provide important insights into disease ...
When Nathan was diagnosed with chronic lymphocytic leukemia (CLL) at just 45 years old, his world turned upside down overnight. As a military veteran and ER nurse, he was no stranger to facing ...
Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...
Venetoclax demonstrated a 91% overall response rate and 44% complete response rate in octogenarians with CLL, comparable to younger cohorts. Common adverse events included neutropenia (37%) and grade ...
Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.
About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results